Recent Updates
Recently added Catalysts
ABBV

AbbVie to Present at the 37th Annual J.P. Morgan Healthcare Conference AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, will participate in the 37th annual J.P. Morgan Healthcare Conference on...

Key Takeaway: NORTH CHICAGO, Ill. , Dec. 20, 2018 /PRNewswire/ -- AbbVie (NYSE: ABBV ), a research-based global biopharmaceutical company, will participate in the 37 th annual J.P. Morgan Healthcare Conference on Wednesday, January 9, 2019 . Michael Severino , M.D., Vice Chairman and President

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+33%
120-day peak, hindsight
Typical move
1.4%
average across 15 past catalysts
Lead asset
paricalcitol
Phase 3 · Secondary Hyperparathyroidism

Full Press Release Details

NORTH CHICAGO, Ill. , Dec. 20, 2018 /PRNewswire/ -- AbbVie (NYSE: ABBV ), a research-based global biopharmaceutical company, will participate in the 37 th annual J.P. Morgan Healthcare Conference on Wednesday, January 9, 2019 . Michael Severino , M.D., Vice Chairman and President, will present at 10:00 a.m. Central time ( 8:00 a.m. Pacific time ).
A live audio webcast of the presentation will be accessible through AbbVie's Investor Relations website at investors.abbvie.com . An archived edition of the session will be available later that day.
AbbVie is a global, research and development-based biopharmaceutical company committed to developing innovative advanced therapies for some of the world's most complex and critical conditions. The company's mission is to use its expertise, dedicated people and unique approach to innovation to markedly improve treatments across four primary therapeutic areas: immunology, oncology, virology and neuroscience. In more than 75 countries, AbbVie employees are working every day to advance health solutions for people around the world. For more information about AbbVie, please visit us at www.abbvie.com . Follow @abbvie on Twitter, Facebook , LinkedIn or Instagram .
Last updated: Dec 20, 2018